Updated Oct 28, 10:19 PM · 60 sources analyzed
Key Takeaways
Today's sources are dominated by ClinicalTrials.gov registry updates — completions and terminations — with zero efficacy data disclosed across all 60 items.
Roche's astegolimab Phase 3 COPD completion is the highest-profile registry update; actual data needed before any competitive or investment conclusion is warranted.
Bayer's finerenone Type 1 Diabetes CKD trial completion signals a potential label-expansion filing in the pipeline, pending data release.
🏆 Winner
Bayer AG — finerenone Phase 3 completion in Type 1 Diabetes CKD advances a potential label expansion that could broaden the Kerendia franchise beyond its current Type 2 Diabetes approval.
📉 Loser
Annexon, Inc. — ANX007 Phase 2 geographic atrophy trial completed with no data disclosed, leaving the program's viability uncertain in a market where two approved complements are already struggling commercially.
🔭 Watch Next
Roche's astegolimab COPD Phase 3 data presentation — expected at a major respiratory conference in 2027 — is the most consequential upcoming readout visible in today's sources, given the scale of the COPD market and the competitive pressure from dupilumab's recent expansion.
Roche's astegolimab Phase 3 COPD trial completes
Hoffmann-La Roche's Phase 3 trial evaluating astegolimab — an IL-33 antibody designed to reduce lung inflammation — in COPD patients has been marked completed on ClinicalTrials.gov (NCT05595642). No efficacy or safety data have been released publicly alongside the status update, leaving investors without signal on whether the drug worked in this indication. COPD remains a large, underserved market, and a successful readout would put astegolimab in direct competition with dupilumab and other IL-axis biologics being evaluated in obstructive lung disease.
ClinicalTrials.gov ↗Hoffmann-La Roche
Astegolimab in Chronic Obstructive Pulmonary Disease (COPD)
The Phase 3 trial (NCT05595642) has been marked completed on ClinicalTrials.gov. Full data have not yet been released; the registry update carries no efficacy or safety disclosure.
Why it matters
A registry completion with no accompanying data release is a holding pattern, not a signal. Roche will need to present full exacerbation-rate and lung-function data at a major respiratory meeting before investors can assess whether astegolimab has a realistic path in COPD alongside its established asthma program.
What to watch
Watch for astegolimab COPD data presentation at ATS or ERS in 2027, and whether Roche files a supplemental indication — the competitive window against dupilumab is narrowing.
AstraZeneca
AZD2693 in Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis
The Phase 2 trial evaluating AZD2693 — a PNPLA3 148M risk allele-targeted therapy given by subcutaneous injection — in non-cirrhotic NASH with fibrosis (NCT05809934) has been marked completed on ClinicalTrials.gov. No efficacy or safety data have been released alongside the status update.
Why it matters
AstraZeneca's bet on genetically stratified NASH patients is strategically differentiated from broad-population fibrosis approaches, but the completion of this trial without data disclosure means the program's viability remains opaque. The NASH field has a long history of Phase 2 signals that failed to translate — AZN will need to show histological improvement, not just biomarker change, to move the needle.
What to watch
Watch for AZD2693 Phase 2 data presentation at AASLD or EASL in 2027, and whether AstraZeneca advances to a genotype-enriched Phase 3 design.
Annexon, Inc.
ANX007 in Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD)
The Phase 2 trial of intravitreal ANX007 in geographic atrophy (NCT04656561) has been marked completed on ClinicalTrials.gov. The trial measured GA lesion growth reduction. Full data have not been released alongside the registry status update.
Why it matters
The GA space has proven brutal for late-stage drugs — approved complements (pegcetacoplan) face slow uptake due to modest absolute benefit and injection burden. Annexon needs to show ANX007's C1q inhibition mechanism delivers meaningfully better lesion-growth slowing than current options, not just statistical significance, to justify further investment.
What to watch
Watch for Annexon's Phase 2 data release or investor presentation in Q4 2026 or Q1 2027 and whether the lesion-growth reduction crosses into clinically meaningful territory (typically defined as ≥20–25% relative slowing).
Apellis Pharmaceuticals, Inc.
Pegcetacoplan (APL-2) in Geographic Atrophy secondary to Age-Related Macular Degeneration
The Phase 3 open-label extension study of pegcetacoplan in geographic atrophy (NCT04770545) has been marked completed on ClinicalTrials.gov. Long-term safety and efficacy data from this extension have not been released alongside the registry update.
Why it matters
Apellis needs clean long-term safety data from this extension to address the vasculitis and endophthalmitis signals that have weighed on Syfovre's commercial trajectory. The absence of a public data release despite trial completion is a gap that investors and retina specialists will be watching closely.
What to watch
Watch for Apellis to publish or present the extension study data at AAO 2027 and whether long-term safety rates confirm or challenge the product label's current risk language.
The Phase 3 trial (NCT05595642) has been marked completed on ClinicalTrials.gov. Full data have not yet been released; the registry update carries no efficacy or safety disclosure.
Why it matters
COPD is a massive commercial opportunity — if astegolimab shows meaningful exacerbation reduction, it could challenge Sanofi/Regeneron's dupilumab, which recently expanded into COPD.
Analysis
A registry completion with no accompanying data release is a holding pattern, not a signal. Roche will need to present full exacerbation-rate and lung-function data at a major respiratory meeting before investors can assess whether astegolimab has a realistic path in COPD alongside its established asthma program.
What to watch
Watch for astegolimab COPD data presentation at ATS or ERS in 2027, and whether Roche files a supplemental indication — the competitive window against dupilumab is narrowing.
The Phase 2 trial evaluating AZD2693 — a PNPLA3 148M risk allele-targeted therapy given by subcutaneous injection — in non-cirrhotic NASH with fibrosis (NCT05809934) has been marked completed on ClinicalTrials.gov. No efficacy or safety data have been released alongside the status update.
Why it matters
PNPLA3-targeted therapies represent a genetically validated approach in NASH; if AZD2693 shows histological benefit, AstraZeneca would enter a precision NASH field that currently lacks approved genotype-specific agents.
Analysis
AstraZeneca's bet on genetically stratified NASH patients is strategically differentiated from broad-population fibrosis approaches, but the completion of this trial without data disclosure means the program's viability remains opaque. The NASH field has a long history of Phase 2 signals that failed to translate — AZN will need to show histological improvement, not just biomarker change, to move the needle.
What to watch
Watch for AZD2693 Phase 2 data presentation at AASLD or EASL in 2027, and whether AstraZeneca advances to a genotype-enriched Phase 3 design.
The Phase 2 trial of intravitreal ANX007 in geographic atrophy (NCT04656561) has been marked completed on ClinicalTrials.gov. The trial measured GA lesion growth reduction. Full data have not been released alongside the registry status update.
Why it matters
Geographic atrophy is a crowded space with pegcetacoplan and avacincaptad pegol already approved; ANX007 would need a differentiated efficacy or dosing profile to carve out commercial ground.
Analysis
The GA space has proven brutal for late-stage drugs — approved complements (pegcetacoplan) face slow uptake due to modest absolute benefit and injection burden. Annexon needs to show ANX007's C1q inhibition mechanism delivers meaningfully better lesion-growth slowing than current options, not just statistical significance, to justify further investment.
What to watch
Watch for Annexon's Phase 2 data release or investor presentation in Q4 2026 or Q1 2027 and whether the lesion-growth reduction crosses into clinically meaningful territory (typically defined as ≥20–25% relative slowing).
The Phase 3 open-label extension study of pegcetacoplan in geographic atrophy (NCT04770545) has been marked completed on ClinicalTrials.gov. Long-term safety and efficacy data from this extension have not been released alongside the registry update.
Why it matters
Long-term extension data for pegcetacoplan (Syfovre) are commercially relevant — the drug's uptake has been constrained by safety signals and questions about durable benefit, making this dataset meaningful for prescribers and payers.
Analysis
Apellis needs clean long-term safety data from this extension to address the vasculitis and endophthalmitis signals that have weighed on Syfovre's commercial trajectory. The absence of a public data release despite trial completion is a gap that investors and retina specialists will be watching closely.
What to watch
Watch for Apellis to publish or present the extension study data at AAO 2027 and whether long-term safety rates confirm or challenge the product label's current risk language.
Bayer's Phase 3 trial of finerenone — an approved non-steroidal mineralocorticoid receptor antagonist (MRA) — in CKD patients with Type 1 Diabetes (NCT05901831) has been marked completed on ClinicalTrials.gov. No outcome data have been disclosed alongside the registry status update.
Why it matters
Finerenone (Kerendia) is already approved for CKD with Type 2 Diabetes; a Type 1 Diabetes indication would meaningfully expand the addressable patient population and extend the drug's commercial lifecycle.
Analysis
This trial completion matters for Bayer's Kerendia franchise — a positive readout in Type 1 Diabetes CKD would open a label expansion that competitors AZ (dapagliflozin) and Novo (semaglutide) cannot easily replicate with their current approved indications. Bayer will need to show that renal and cardiovascular protection extends across insulin-dependent patients.
What to watch
Watch for Bayer's Phase 3 data presentation at ASN Kidney Week or ERA 2027 and whether the company files a supplemental NDA for the Type 1 Diabetes CKD label expansion.
Computational design of novel PDE4 inhibitors for plaque psoriasis
Researchers used computational methods to design two novel phosphodiesterase-4 (PDE4) inhibitors — enzymes that regulate inflammation — with structural profiles potentially distinct from existing approved agents like apremilast and roflumilast cream.
Why it matters
If the computationally guided candidates demonstrate improved selectivity or reduced off-target effects (nausea is the primary dose-limiting issue with current PDE4 inhibitors), they could offer a path to better-tolerated oral or topical therapies in an indication where biologics dominate the premium tier.
Analysis
This is early-stage computational work from a preprint, so clinical translation is speculative — but the psoriasis market is large enough that any molecule with a credible tolerability advantage over apremilast would attract licensing interest. The real question is whether in vitro potency holds in cellular and animal models before anyone puts capital behind these structures.
What to watch
Watch for peer-reviewed publication and in vivo efficacy data in mouse psoriasis models, which would be the minimum bar before this science attracts pharma partnership discussions.
Randomized Phase 2 of decitabine for poor graft function after allogeneic stem cell transplant completes
The First Affiliated Hospital of Soochow University completed a randomized Phase 3 trial (NCT05907499) of low-dose decitabine — a DNA methyltransferase inhibitor used in blood cancers — for poor graft function (PGF) after allogeneic hematopoietic stem cell transplant (allo-HSCT), a complication with few established treatment options; no outcome data have been released.
Why it matters
PGF after allo-HSCT remains a clinical problem with no approved therapy; if decitabine demonstrates improved donor-cell engraftment, it would validate epigenetic modulation as a post-transplant intervention and could influence institutional protocols globally.
Analysis
This is an investigator-led academic trial with no disclosed commercial sponsor — the clinical question it addresses is real, but the path from a completed Chinese single-center randomized trial to a globally adopted treatment standard requires peer-reviewed publication and independent replication. Biotech companies developing novel engraftment-enhancing therapies should monitor the outcome data when published.
What to watch
Watch for publication of results in a peer-reviewed hematology journal, which would establish whether low-dose decitabine becomes a standard-of-care option or remains experimental in PGF management.
Phase 2 of GLP-1R genetic variation on beta-cell function completes
A completed NIH-sponsored Phase 3 physiological study (NCT04466566) investigated how genetic variation in the GLP-1 receptor gene affects beta-cell insulin secretion in non-diabetic individuals, with findings not yet publicly disclosed.
Why it matters
Understanding GLP-1 receptor pharmacogenomics — why some individuals respond robustly to GLP-1 agonists while others do not — could inform patient stratification strategies for incretin-based drugs and guide next-generation receptor agonist design.
Analysis
Pharmacogenomic stratification for GLP-1 therapies is increasingly relevant as the class expands into cardiometabolic, renal, and CNS indications — any genetic predictor of response or non-response would be valuable intellectual property for drug developers and diagnostics companies seeking companion diagnostic opportunities.
What to watch
Watch for NIH publication of this dataset in a metabolism or endocrinology journal, which could establish whether GLP1R genotyping has clinical utility for patient selection in incretin therapy programs.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
No coverage today
None of your tracked companies appeared in today's sources.